You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.
Use of the Oncomine Focus Assay led to an expansion of genomic profiling for all guideline-recommend alterations and the identification of a broad set of clinically relevant targets.
New genetic studies are providing insights into the molecular changes that occur as benign moles transition to melanoma and spread to other parts of the body by metastasis.
The company said it will seek FDA approval for the assay, an expanded version of FoundationACT, as a CDx for targeted therapies and as a tumor mutation profiling assay.
Foundation Medicine will provide genomic profiling for the EORTC's Screening Patients for Efficient Clinical Trial Access program.